Get the app
USHealthcare

Perrigo Company PLC (PRGO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$13.48-0.44%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$1.02B
Revenue YoY
-3.2%
Net profit
$74.5M
EPS
$0.50
EPS estimate
$0.31
Net margin
7.3%

EPS came in at 0.50 against a street estimate of 0.31 — a beat of 61.3%.

Key statistics

Market cap
$1.90B
Forward P/E
5.9
P/B
0.75
Book value
$18.14
EPS (TTM)
$-12.35
Dividend yield
8.54%
52-week high
$20.70
52-week low
$8.81
50-day MA
$12.19
200-day MA
$12.22
Beta
0.60

Analyst view

Analysts rate Perrigo Company PLC a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $16.50.

Shareholding

Insiders
0.40%
Institutions
114.63%

Largest institutional holders

FundStake
BlackRock Inc12.34%
T. Rowe Price Associates, Inc.9.64%
Neuberger Berman Group LLC7.54%
Vanguard Portfolio Management, LLC5.87%
Fuller & Thaler Asset Management Inc5.52%
State Street Corp5.21%
Vanguard Capital Management, LLC4.47%
Dimensional Fund Advisors, Inc.3.94%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
PERRIGO COMPANY PLC - FORM 10-Q SUMMARY Quarter Ended June 27, 2026 --- HEADLINE NUMBERS • Net sales Q2 2026: $1,022.8 million (down 3.2% vs Q2 202
2026-08-05
Results announced · Q3 2026
PERRIGO COMPANY PLC - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Core Net Sales: $907 million, down 3.1% year-over-year (3.5% organic decline) • A
2026-08-05
Board / officer change · Q2 2026
PERRIGO COMPANY PLC - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial performance data disclosed in this filing • Filing date: June 29, 2026 • Comp
2026-07-06
Board / officer change · Q2 2026
PERRIGO COMPANY PLC - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Board Expansion & New Appointments: Board size increased from 8 to 10 directo
2026-06-30
Board / officer change · Q2 2026
PERRIGO COMPANY PLC - 8-K SUMMARY HEADLINE NUMBERS • CEO Departure: Patrick Lockwood-Taylor resigned effective immediately on June 7, 2026, as Presi
2026-06-08
Quarterly report · Q1 2026
PERRIGO COMPANY PLC - Q1 2026 SUMMARY HEADLINE NUMBERS • Net sales: $969.2 million (Q1 2026) vs. $1,043.9 million (Q1 2025) – decline of 7.2% • Net
2026-05-06
Proxy statement · Q2 2026
PERRIGO COMPANY PLC – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine director nominees to serve until th
2026-03-20
Annual report FY2025
PERRIGO COMPANY PLC - FORM 10-K (YEAR ENDED DECEMBER 31, 2025) HEADLINE NUMBERS • Market Capitalization (as of June 27, 2025): $3,650,573,391 • Outs
2026-02-26

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.29 / share
ex-date Aug 28, 2026 · pay Sep 15, 2026
2026-08-28
Dividend$0.29 / share
ex-date May 29, 2026 · pay Jun 5, 2026
2026-05-29
Dividend$0.29 / share
ex-date Mar 2, 2026 · pay Mar 24, 2026
2026-03-02
Dividend$0.29 / share
ex-date Nov 28, 2025 · pay Dec 16, 2025
2025-11-28
Dividend$0.29 / share
ex-date Aug 29, 2025 · pay Sep 16, 2025
2025-08-29

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Perrigo Company PLC — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.